Suchergebnisse - "Masaquel, Anthony"

PubPharm (72)

1

Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma

enthalten in: Haematologica | 2023

von Maurer, M. | Casulo, C. | Larson, M. | +20

2

Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Burke, J. | Masaquel, A. | Wang, R. | +5

3

US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma

enthalten in: Journal of medical economics | 2023

von Matasar, M. | Masaquel, A. | S Ho, R. | +7

4

Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE) : a multicentre cohort study

enthalten in: The Lancet. Haematology | 2022

von Casulo, C. | Larson, M. | Lunde, J. | +21

CommentIn: Lancet Haematol. 2022 Apr;9(4):e241-e242. - PMID 35358433

5

Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia : Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine

enthalten in: Clinical lymphoma, myeloma & leukemia | 2022

von Danilov, A. | Yimer, H. | Boxer, M. | +7

6

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma

enthalten in: Journal of managed care & specialty pharmacy | 2021

von Spencer, S. | Guzauskas, G. | FeLizzi, F. | +4

7

Real-world practice patterns and outcomes in Veterans with relapsed/refractory diffuse large B-cell lymphoma

enthalten in: Future oncology (London, England) | 2021

von Chien, H. | Morreall, D. | Patil, V. | +10

8

US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma

enthalten in: Journal of comparative effectiveness research | 2020

von Betts, K. | Thuresson, P. | Felizzi, F. | +5

ErratumIn: J Comp Eff Res. 2021 Mar;10(4):337. - PMID 33416405

9

Maintenance rituximab in Veterans with follicular lymphoma

enthalten in: Cancer medicine | 2020

von Halwani, A. | Rasmussen, K. | Patil, V. | +9

10

Maintenance rituximab in Veterans with follicular lymphoma

enthalten in: Cancer Medicine | 2020

von Halwani, A. | Rasmussen, K. | Patil, V. | +9

1
2
3
4
5
6
7
8
Nächster »
[8]